DailyStocks Stock Article Search

https://seekingalpha.com/article/4667172-takeda-pharmaceutical-company-limited-tak-q3-2023-earnings-call-transcript?source=feed_tag_japan Feb 02, 2024 - Takeda Pharmaceutical Company Limited (NYSE:NYSE:TAK) Q3 2023 Earnings Conference Call February 1, 2024 8:00 AM ETCompany ParticipantsChristopher O’Reilly –... 0

https://www.zacks.com/stock/news/2238576/are-investors-undervaluing-takeda-pharmaceutical-co-tak-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2238576 Mar 11, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. 0

https://www.zacks.com/stock/news/2262569/all-you-need-to-know-about-takeda-pharmaceutical-co-tak-rating-upgrade-to-strong-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2262569 Apr 25, 2024 - Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). 0

https://www.zacks.com/stock/news/2263229/down-5-9-in-4-weeks-here-s-why-takeda-pharmaceutical-co-tak-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2263229 Apr 26, 2024 - Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. 0

https://www.zacks.com/stock/news/2238787/takeda-pharmaceutical-co-tak-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2238787 Mar 11, 2024 - Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 0

https://www.zacks.com/stock/news/2245547/opko-health-opk-and-entera-bio-announce-data-for-glp-2?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245547 Mar 25, 2024 - OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath. 0